[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614792":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":49,"collaborators":52,"id":79,"slug":80,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":81,"sex":87,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":18,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":18,"overallStatus":101,"whyStopped":18,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},{"fullName":5,"class":6},"Beijing Anzhen Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"CA330 Group","EXPERIMENTAL","CA330 Cytokine Adsorption Column and Standard Cardiopulmonary Bypass Management",[13],"Device: CA330 Cytokine Adsorption Column",{"label":15,"type":16,"description":17,"interventionNames":18},"non-CA330 Group","NO_INTERVENTION","Standard Cardiopulmonary Bypass Management Alone",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DEVICE","CA330 Cytokine Adsorption Column","CA330 Cytokine Adsorption Column (Experimental Arm):\n\nThe CA330 cytokine adsorption column is a novel hemoperfusion device integrated into the cardiopulmonary bypass (CPB) circuit. During CPB, the column removes specific circulating substances, including inflammatory mediators and residual anticoagulant\u002Fantiplatelet drugs, via adsorption. Patients in this arm will undergo non-elective cardiac surgery with standard anesthesia, surgery, and perioperative management, with the addition of the CA330 device placed inline during CPB.",[9],[26],{"name":27,"affiliation":5,"role":28},"Xiaotong Hou","STUDY_CHAIR",[30],{"name":31,"role":32,"phone":33,"phoneExt":18,"email":34},"Xing Hao","CONTACT","+8664456328","haoxing131@126.com",[36],{"facility":37,"status":18,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":18},"Center for Cardiac Intensive Care, Beijing Anzhen Hospital, Capital Medical University","Beijing","Beijing Municipality","100029","China","CN",{"type":44,"coordinates":45},"Point",[46,47],116.39723,39.9075,{"lat":47,"lon":46},{"type":50,"investigatorFullName":27,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Professor",[53,55,57,59,61,63,65,67,69,71,73,75,77],{"name":54,"class":6},"Shanghai Zhongshan Hospital",{"name":56,"class":6},"Wuhan Asia Heart Hospital",{"name":58,"class":6},"Xijing Hospital",{"name":60,"class":6},"West China Hospital",{"name":62,"class":6},"Guangdong Provincial People's Hospital",{"name":64,"class":6},"Second Xiangya Hospital of Central South University",{"name":66,"class":6},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",{"name":68,"class":6},"Henan Provincial Chest Hospital",{"name":70,"class":6},"Army Medical University, China",{"name":72,"class":6},"Tongji Hospital",{"name":74,"class":6},"Xiangya Hospital of Central South University",{"name":76,"class":6},"The First Affiliated Hospital of Zhengzhou University",{"name":78,"class":6},"First Affiliated Hospital Xi'an Jiaotong University","100614792","clear-trial-ca330-cytokine-adsorption-column-for-anticoagulantantiplatelet-patients-in-non-elective-cpb-surgery-100614792",false,"NCT07284199","CLEAR Trial: CA330 Cytokine Adsorption Column for Anticoagulant\u002FAntiplatelet Patients in Non-Elective CPB Surgery.","A Multicenter Randomized Controlled Trial of the CA330 Haemoadsorption Device in Patients for Limiting Excess Anticoagulation in Non-elective caRdiac Surgery With Cardiopulmonary Bypass","CLEAR","Inclusion Criteria:\n\n* Patients scheduled to undergo non-elective cardiovascular surgery requiring cardiopulmonary bypass;\n* Patients currently receiving one or more of the following medications - indobufen, ticagrelor, warfarin, cilostazol, dabigatran, rivaroxaban, or apixaban - with the last dose administered within the drug washout period.\n\nExclusion Criteria:\n\n* Patients with a history of chronic liver failure, stage 5 chronic kidney disease (CKD5), or requiring regular dialysis;\n* Patients in special physiological states: pregnancy or puerperium;\n* Patients with advanced-stage malignancy or scheduled cardiovascular surgery related to tumor management;\n* Patients with allergic reactions to cytokine adsorption column resin or related components;\n* Patients with known bleeding risk due to hematologic disorders such as heparin-induced thrombocytopenia, hemophilia, or acute sickle cell crisis;\n* Patients with severe infection, including severe sepsis.","ALL","18 Years","80 Years",{"count":91,"type":92},120,"ESTIMATED","INTERVENTIONAL",[95],"NA","The goal of this clinical trial is to evaluate whether the CA330 cytokine adsorption column can reduce perioperative severe bleeding adverse events in patients receiving anticoagulant and\u002For antiplatelet therapy who undergo non-elective cardiac surgery with cardiopulmonary bypass.\n\nThe main questions it aims to answer are:\n\n* Does the use of the CA330 cytokine adsorption column lower the incidence of perioperative severe bleeding compared with standard care?\n* Does the intervention improve short-term clinical outcomes, such as transfusion requirements, reoperation rates for bleeding, or overall postoperative recovery?\n\nIf there is a comparison group: Researchers will compare patients treated with the CA330 cytokine adsorption column versus patients receiving standard cardiopulmonary bypass management to see if cytokine adsorption provides additional safety and efficacy benefits.\n\nParticipants will:\n\n* Undergo non-elective cardiac surgery requiring cardiopulmonary bypass.\n* Be randomly assigned to receive either the CA330 cytokine adsorption column integrated into the CPB circuit (intervention arm) or standard CPB management without the device (control arm).\n* Be monitored for perioperative bleeding outcomes, transfusion needs, reoperation rates, and overall postoperative prognosis.",[98,99,100],"CABG","Aortic Dissection","Valvular Heart Diseases","NOT_YET_RECRUITING","2025-12-14",{"date":104,"type":105},"2025-12-16","ACTUAL",{"date":107,"type":92},"2025-12-15",{"date":109,"type":92},"2028-06-30",{"name":5,"class":6},1]